
|Videos|August 1, 2011
Dr. West Discusses Anticipated Future Clinical Trials
Author(s)H. Jack West, MD
Dr. Jack West from the Swedish Cancer Institute Talks About Anticipated Future Clinical Trials
Advertisement
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, explains his anticipation to see an overall survival benefit emerge from the PARAMOUNT study examining continuation maintenance with pemetrexed in non-small cell lung cancer. He mentions a strong interest in clinical trials examining next generation studies such as crizotinib in patients that do not have the ALK rearrangement and BRAF targeted therapies which are still in their infancy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































